Galectin Therapeutics Inc
GALT
Get informed when a big investor buys or sells
+ FollowMarket Cap$186.05M
Close$
$-1.82
146.3% downside
Current Fair Value
146.3% downsideOvervalued by 146.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $186.05 Million |
|---|---|
| Enterprise Value | $307.64 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.48 |
| Beta | 0.49 |
| Outstanding Shares | 65,782,000 |
Return
| Return on Equity | 20.16% |
|---|---|
| Return on Assets | -166.58% |
| Return on Invested Capital | 168.61% |
Valuation & Multiples
| P/E Ratio | -6.94 |
|---|---|
| PEG | 14.58 |
| Price to Sales | - |
| Price to Book Ratio | -1.96 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 21.59 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.44 |
| Debt to Equity | -1.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0558▼ 5.33% |
|---|---|
| Total Calls | 1,513,500▲ 108.64% |
| Total Puts | 84,400▲ 6.70% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 21.71%▲ 3.69% |
|---|---|
| Total Invested | $38.56M▼ 19.42% |
| Investors Holding | 105▲ 3.00% |
ESG Score
No data
About Galectin Therapeutics Inc
CEO: Harold Shlevin